Cantor Fitzgerald assumed coverage of Aclaris Therapeutics (ACRS) with an Overweight rating. Cantor is bullish on the TSLP and IL-4R bispecific, which looks differentiated, and even early ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback